Transitioning complex immunoassay blood tests directly to the point-of-care More »
Rapidly identifying disease-specific antibodies More »
Addressing novel biological mechanisms for Parkinson’s disease, respiratory diseases, supportive care, and protein up-regulation More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.